Overview

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers

Status:
Terminated

Trial end date:
2020-12-07

Target enrollment:

Participant gender:

Summary

Primary objective: To assess the safety and tolerability of EXPAREL® administered as a single intrathecal injection in healthy volunteers Secondary objective: To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile of EXPAREL® administered as a single intrathecal injection in healthy volunteers

Phase:

Phase 1

Details

Lead Sponsor:

Pacira Pharmaceuticals, Inc

Treatments:

Bupivacaine